China’s National Medical Products Administration has approved Sino Biopharmaceutical Ltd.’s rovadicitinib, branded as Anxu, for first-line treatment of adults with intermediate- or high-risk primary myelofibrosis, as well as post polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis. Read More

In a boon for licensee Bristol Myers Squibb Co., Systimmune Inc.’s next-generation cancer drug, izalontamab brengitecan (iza-bren), hit both progression-free survival and overall survival endpoints in a phase III trial of Chinese patients with advanced triple-negative breast cancer. Read More

In an all-cash transaction valued at €780 million (US$920 million), Asahi Kasei Corp. offered to buy Aicuris Anti-infective Cures AG, expanding its infectious disease portfolio with a marketed cytomegalovirus product and a herpes treatment nearing an NDA. Read More

GSK plc will pay Frontier Biotechnologies Inc. $40 million up front and up to $963 million in milestone payments to license two of Frontier’s small interfering RNA-based assets in the field of immunology. Read More

GSK plc is paying $950 million cash to acquire 100% of 35Pharma Inc.’s equity and pipeline, including phase II-ready candidate HS-235 for pulmonary hypertension. The acquisition agreement comes a day after GSK added two small interfering RNA assets from Nanjing, China-based Frontier Biotechnologies Inc. through a license deal reaching up to $1 billion. Read More

China’s National Medical Products Administration has accepted for review Jiuyuan Genetic Biopharmaceutical Co. Ltd.’s drug application for Jikeqin, a biosimilar product to Novo Nordisk A/S’s Wegovy (semaglutide) for obesity. Read More

U.S. scrutiny of China’s trade practices, especially in the biotech sector, continues to escalate as the U.S. International Trade Commission launches two factfinding investigations Congress mandated in the fiscal 2026 appropriations. Read More

The BioWorld Biopharmaceutical Index finished 2025 up 24.07%, building slightly on its 23% gain recorded at the end of November. While the increase trailed the Nasdaq Biotechnology Index’s 32.4% rise for the year, it outperformed the broader Dow Jones Industrial Average, which advanced 12.97%. Read More

Biopharma and med-tech companies in Asia-Pacific raising money in public or private financings: Respiree, Slate Medicines, Dartsbio. Read More

Clinical updates for biopharma and med tech in Asia-Pacific, including data readouts and publications: Argo, Immunexpress, Immvira, Novo Nordisk, Shionogi, United Laboratories International, Viiv. Read More

Biopharma and med-tech happenings in Asia-Pacific, including deals and partnerships, and other news in brief: Alchemedicine, Antengene, Arrotex, Asahi Kasei, Chugai, Clinect, Daiichi Sankyo, Epredia, Formosa, Frontier, George Medicines, Grünenthal, GSK, IDT Biologika, Jazz, Junshi, Mindpeak, Orient Europharma, Pfizer, PHC Holdings, Roche, Sarepta, Sciwind, SK Bioscience, Sumitomo, Sylamorebio, Vaxxas. Read More

Regulatory snapshots for biopharma and med tech in Asia-Pacific, including global submissions and approvals, and other regulatory decisions and designations: Asieris, Cstone, Dr. Reddy’s, Optellum, Photocure. Read More